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Background: Hexokinase I is the pacemaker of glycolysis in brain tissue. The
type I isozyme exhibits unique regulatory properties in that physiological levels
of phosphate relieve potent inhibition by the product, glucose-6-phosphate
(Gluc-6-P). The 100 kDa polypeptide chain of hexokinase I consists of a
C-terminal (catalytic) domain and an N-terminal (regulatory) domain. Structures
of ligated hexokinase I should provide a basis for understanding mechanisms of
catalysis and regulation at an atomic level.
Results: The complex of human hexokinase I with glucose and Gluc-6-P
(determined to 2.8 Å resolution) is a dimer with twofold molecular symmetry.
The N- and C-terminal domains of one monomer interact with the C- and
N-terminal domains, respectively, of the symmetry-related monomer. The two
domains of a monomer are connected by a single α helix and each have the fold
of yeast hexokinase. Salt links between a possible cation-binding loop of the
N-terminal domain and a loop of the C-terminal domain may be important to
regulation. Each domain binds single glucose and Gluc-6-P molecules in
proximity to each other. The 6-phosphoryl group of bound Gluc-6-P at the
C-terminal domain occupies the putative binding site for ATP, whereas the
6-phosphoryl group at the N-terminal domain may overlap the binding site for
phosphate.
Conclusions: The binding synergism of glucose and Gluc-6-P probably arises
out of the mutual stabilization of a common (glucose-bound) conformation of
hexokinase I. Conformational changes in the N-terminal domain in response to
glucose, phosphate, and/or Gluc-6-P may influence the binding of ATP to the
C-terminal domain.
Introduction
Hexokinase (ATP: D-hexose 6-phosphotransferase, EC
2.7.1.1) catalyzes the phosphorylation of glucose, using
ATP as a phosphoryl donor. Four isoforms of hexokinase
exist in mammalian tissue [1]. Hexokinase isoforms I, II
and III have molecular weights of approximately 100,000
and are monomers under most conditions. Amino acid
sequences of isoforms I–III are 70% identical [2]. More-
over, the N- and C-terminal halves of isoforms I–III have
similar amino acid sequences, probably as a result of gene
duplication and fusion [3–6]. Hexokinase isoform IV
(glucokinase) has a molecular weight of 50,000, similar to
that of yeast hexokinase. Glucokinase exhibits (as does
yeast hexokinase) significant sequence similarity to the N-
and C-terminal halves of isoforms I–III.
Despite sequence similarities, the functional properties of
hexokinase isoforms differ significantly. Isoform I (here-
after, hexokinase I) governs the rate-limiting step of gly-
colysis in brain and the red blood cell [7,8]. The reaction
product, glucose-6-phosphate (Gluc-6-P), inhibits both
isoforms I and II (but not isoform IV) at micromolar
levels. Inorganic phosphate (Pi), however, relieves Gluc-
6-P inhibition of only hexokinase I. The C-terminal
domain of hexokinase I possesses catalytic activity, whereas
the N-terminal domain by itself has no activity [9,10], but
is involved in the Pi-induced relief of product inhibition
[9,11]. In contrast, both the C- and N-terminal halves have
comparable catalytic activity in isoform II [12]. Thus,
among hexokinase isoforms, brain hexokinase exhibits
unique regulatory properties in that physiological levels of
Pi can reverse inhibition due to physiological levels of
Gluc-6-P [13–15].
Although crystal structures of yeast hexokinases [16,17]
provide a rough framework on which to base investigations
of brain hexokinase, they cannot provide the kind of infor-
mation necessary for an understanding of the complex set
of biochemical phenomena exhibited by the mammalian
enzyme. Investigators have proposed two mechanisms for
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inhibition of brain hexokinase by Gluc-6-P: the first sug-
gests that Gluc-6-P binds tightly to the N-terminal
domain of hexokinase I and inhibits the catalytic process
at the C-terminal domain [18]; and the second proposes
that Gluc-6-P binds to the active site of the C-terminal
domain [19]. Given that glucose and Gluc-6-P bind syner-
gistically to hexokinase I, the binding of Gluc-6-P as an
inhibitor cannot overlap the binding site of glucose [14].
Indeed, proponents of the second mechanism suggest that
the 6-phosphoryl group of Gluc-6-P binds to the γ-phos-
phoryl site for ATP [19]. A recent report of the prelimi-
nary crystal structure of rat hexokinase I at 3.2 Å, revealed
the domain structure of the dimeric state of hexokinase I
and putative sites for glucose and Gluc-6-P, but no details
of ligand interaction [20].
The crystallographic structure at 2.8 Å resolution, reported
here, of the complex of recombinant human brain hexo-
kinase with glucose and Gluc-6-P, reveals a homodimer
of hexokinase I monomers with pairs of glucose and
Gluc-6-P molecules bound in proximity to each other at
the N- and C-terminal domains. On the basis of this
structure, we propose a mechanism that accounts for the
observed binding synergism between glucose and Gluc-
6-P. In addition, we suggest plausible models for reg-
ulation which couple conformational changes in the
N-terminal domain to perturbations in the binding pocket
for ATP at the C-terminal domain.
Results and discussion
Quality of the structure
Crystals of human hexokinase I in complex with glucose
and Gluc-6-P (P21; a = 83.44 Å, b = 121.83 Å, c = 122.53 Å,β = 92.6°) diffract to a nominal resolution of 2.6 Å at 4°C
and to 2.2 Å at 100K, using a synchrotron radiation source
(SSRL, BL7-1). Data were collected to a limiting resolution
of 2.8 Å at 4°C (Table 1). Rapid freezing proved disruptive
to crystals; data collected at 100K reflected significant
mosaicity and behaved poorly in refinement. Although the
structure reported here was from a crystal grown in the pres-
ence of Gluc-6-P and transferred to a glucose/Gluc-6-P
solution prior to data collection, the structure is identical to
one obtained from crystals grown in the presence of glucose
and Gluc-6-P. We present here only our best model in
terms of resolution and refinement statistics.
Electron density begins at the approximate position of
residue 13 and continues without interruption to the
approximate position of residue 914. The model, however,
begins with residue 16 and ends at 914, leaving the inter-
pretation of weak electron density at the N and C termini
to later cycles of refinement and model building. On the
basis of N-terminal sequence analyses of recombinant
human hexokinase I, isolated from Escherichia coli strain
BL21(DE3), the first ten residues are missing (HJF,
unpublished data). The recombinant enzyme has residues
11–917 (907 residues total), whereas the DNA sequence
indicates a polypeptide of 917 amino acids. Hence, the
electron density is present for all but the first two and last
two amino acids of the polypeptide chain.
The model reported from refinement has good geometry
and reasonable R factors (Table 1). The uncertainty in the
positions of atoms is approximately 0.3 Å. An analysis of
the model using PROCHECK [21] indicates that all
residues fall within the generously allowed region of the
Ramachandran plot and that all other categories of geome-
try are as good or better than those of a typical structure of
2.8 Å resolution. Thermal parameters for the model vary
from 5 to 100 Å2.
Secondary, tertiary and quaternary structure
The amino acid sequence used in refinement is approxi-
mately 30% identical to that of yeast hexokinase A, as
derived from its cDNA (Figure 1) and a refined model of
the crystal structure of glucose-bound yeast hexokinase A
(HDB et al., unpublished data). The secondary structure
for hexokinase I is essentially identical to that of the yeast
enzyme as it was first presented by Steitz and colleagues
[16,17]. In assigning secondary structure in hexokinase I
(Figure 1), we adopted wherever possible the corresponding
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Table 1
Statistics of data collection and refinement.
Resolution limit (Å) of data 2.8
No. of measurements 113,243
No. of measurements > 1σ 104,339
No. of rejected measurements 612
No. of unique reflections 58,613
Completeness of data (%) 96.9
Completeness of data in last shell 88.0
(2.9–2.8 Å) (%)
Rsym* 0.055
Resolution range for refinement (Å) 8–2.8
No. of reflections in refinement† 55,607
Total number of atoms 14,324
Total number of solvent sites 146
R factor‡ 20.0
Rfree§ 27.0
Mean B values (Å2)
entire protein 44
N-terminal domain (chains A/B) 58/46
C-terminal domain (chains A/B) 35/39
waters 46
glucose N-terminal domain (chains A/B) 52/17
glucose C-terminal domain (chains A/B) 21/23
Gluc-6-P N-terminal domain (chains A/B) 57/37
Gluc-6-P C-terminal domain (chains A/B) 13/32
Root mean squared deviations
bond lengths (Å) 0.008
bond angles (°) 1.28
*Rsym = ΣjΣi | Iij– <Ij> | / ΣiΣj Iij. †Only reflections with |Fobs|> 2σ(Fobs)
were used in the refinement. ‡R factor = Σ||Fobs|–|Fcalc||/Σ|Fobs|, for all
reflections |Fobs|> 0. §R factor based on 7% of the data excluded from
refinement.
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Figure 1
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Structure
Sequence alignment, secondary structure and conformational
divergence of the N- and C-terminal domains of human hexokinase I
(HKI) and yeast hexokinase (HKA). Residues highlighted in yellow are
identical for at least two of the three domains (N-terminal, C-terminal,
yeast). Red sequence letters for yeast hexokinase represent Cα
atoms that deviate from corresponding carbon atoms of the 
C-terminal domain of hexokinase I by more than 2.3 Å after
superposition. Red sequence letters for the N-terminal domain
represent Cα atoms that deviate from corresponding carbon atoms
of the C-terminal domain by more than 1.5 Å after superposition. The
green letters G, P and A on the top line mark residues in contact with
glucose, Gluc-6-P and the modeled position of ADP, respectively.
The assignment of secondary structure for the N- and C-terminal
domains appears on the bottom line. On the basis of DNA
sequencing (HJF and Tsuei-Yun Fang, unpublished data), the
sequence used in the refinement differs at two positions relative to
the deposited sequence [52] for human hexokinase I: Asn730 has
become Asp730 and Met776 has become Leu776. The sequence
for yeast hexokinase is derived from its cDNA [53].
boundaries and names of secondary elements of the yeast
enzyme. Nonetheless, human hexokinase I has two addi-
tional, single-turn α helices (α2′ and α11′) and one addi-
tional β strand (β7′). No disulfide bonds are evident, but
four pairs of cysteine residues (217, 224; 237, 256; 665,
672; and 685, 704) have sidechain atoms in van der Waals
contact. The contacts involve atom Sγ of one cysteine with
atom Cβ of another; the formation of disulfide bonds with
good geometry would require significant conformational
change in the protein.
The fold of the polypeptide chain for the N- and C-termi-
nal domains corresponds closely to that of yeast hexokinase
(Figure 2). As with the yeast enzyme, the N- and C-termi-
nal domains are each comprised of two subdomains (called
large and small, see Figure 2 for definitions). The spatial
relationship between the large and small subdomains in
both the N- and C-terminal halves of hexokinase I is
essentially identical to that of the glucose-bound complex
of yeast hexokinase [17]. Steitz and colleagues have called
this the closed conformation [22]. Superposition of the C-
terminal domain onto yeast hexokinase and onto the N-
terminal domain (Figure 3; see also Materials and methods
section) reveals a region of the large subdomain which
adopts different relative positions. We call this structural
element, which corresponds to residues 766–810 of the
C-terminal domain, the flexible subdomain. On the basis
of model building (see below) the flexible subdomain
probably interacts with the base of ATP. The structural
differences in the flexible subdomain of the N-terminal
half may prevent the productive binding of ATP and
thereby be responsible for the absence of catalytic activity
in the N-terminal domain. As discussed below, the flexible
subdomain of the C-terminal half may be involved in ATP
binding and in regulation of hexokinase I.
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Figure 2
Domain organization and intermolecular
contacts of hexokinase I. (a) Spatial
relationships of domains and subdomains
comprising a monomer of the hexokinase I
dimer. The N- and C-terminal domains are
each divided into subdomains. Residues
75–209 and 448–465 of the N-terminal
domain, and residues 523–657 and 896–913
of the C-terminal domain are in yellow and
correspond to the small subdomain of yeast
hexokinase. The remaining residues (colored
white and purple) correspond to the large
subdomain of yeast hexokinase. Residues
318–363 of the N-terminal domain and
residues 766–811 of the C-terminal domain
are in purple and correspond to the flexible
subdomain described in the text. Glucose
(red) and Gluc-6-P (blue) are represented by
space-filling models. (b) Interchain contacts of
the hexokinase I dimer. The space-filling image
corresponds in orientation to (a). The red
through to white surface colors represent
distances (red closest, 3.4 Å; white furthest,
6.1 Å) to the nearest atom of the monomer
related by molecular symmetry (polypeptide
trace in purple). The six contact regions,
labeled 1, 2, 3, 4, 5 and 6, correspond to the
subheadings of Table 2.
Table 2
Residue pairs involved in interchain or interdomain contacts
less than 3.5 Å.
Interface name* Residue pair
Interchain 1–6 Glu280A Lys558B
Arg283A Ile559B†
Arg331A‡ Tyr588B†
Interchain 2–5 Gly179A‡ Glu894B
Interchain 3–4 Asp54A† Gln799B
Phe55A† Gln799B
Thr58A Gln799B
Interdomain N–C Asp251A Arg801A
Glu252A Arg801A
Glu252A Cys813A‡
*Interfaces are defined in Figure 2. †The backbone carbonyl group is
involved in the interaction. ‡The backbone amide group is involved in
the interaction.
Interchain and interdomain contacts
The interface between polypeptide chains of the dimer
involves six contact regions (Figure 2; Table 2). The mol-
ecular symmetry of the dimer, however, requires that the
six interfaces divide into two essentially duplicate sets of
three interfaces. The three, symmetry-unique interfaces
(labeled 1–6, 2–5 and 3–4 in Table 2) involve only a small
number of residues and, at most, six hydrogen bonds of
good geometry. Although hexokinase I has one tight
binding site each for glucose and Gluc-6-P [14,23,24],
other studies suggest additional weak binding sites for
Gluc-6-P and glucose at the N-terminal and/or C-terminal
domains [9,19,24,25]. Increasing concentrations of hexo-
kinase I and Gluc-6-P favor dimerization [26], and the
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Figure 3
Superposition of hexokinase domains. (a) N-
terminal domain (brown) superimposed onto
the C-terminal domain (black), showing the
correspondence in positions of glucose and
Gluc-6-P. Black ligands (glucose and Gluc-6-
P) are associated with the C-terminal domain,
whereas magenta ligands are associated with
the N-terminal domain. The flexible subdomain
of the N-terminal domain is in blue. (b) Yeast
hexokinase (brown) superimposed onto the C-
terminal domain (black), showing the
correspondence of the sulfate anion site
(magenta) and glucose site (magenta) in yeast
hexokinase to Gluc-6-P (black) and glucose
(black) of the C-terminal domain. The loop
86–91 of yeast hexokinase (blue),
corresponding to loop 532–537 of the C-
terminal domain, does not interact with the
sulfate anion. (The illustration was generated
with MOLSCRIPT [54].)
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Structure
crystal form reported here grows in the presence of milli-
molar glucose and Gluc-6-P or in the presence of Gluc-6-P
alone at concentrations above 1 mM. (The apparent insen-
sitivity of crystallization experiments to added glucose
may arise from glucose contamination of the Gluc-6-P
solution. Only a 0.1% glucose contamination would satu-
rate the high-affinity binding site for glucose.) All of these
findings are consistent with ligand-induced stabilization of
the closed conformation of both the N- and C-terminal
domains in order to promote dimerization.
Intrachain contacts between the N- and C-terminal
domains involve the spanning helix (α1 of the C-terminal
domain) and an additional region of polar contacts
(Figures 2 and 4; Table 2). This region of polar contacts
involves loop 796–813 of the C-terminal domain (which also
participates in the 3–4 interface between polypeptide
chains of the dimer and is part of the flexible subdomain,
defined above) and loop 242–253 of the N-terminal domain.
If the spanning helix (α1 of the C-terminal domain) fixes
the position of the small subdomain of the N-terminal half
relative to the large subdomain of the C-terminal half
(Figure 2), then a change from the closed to the open con-
former of the N-terminal domain would alter the position of
loop 242–253 relative to loop 796–813. Hence, interactions
at the ligand-binding sites of the N-terminal domain could
44 Structure 1998, Vol 6 No 1
Figure 4
The hexokinase I dimer as viewed down its
molecular twofold axis. (a) Stereoview of a Cα
trace of the hexokinase dimer as viewed down
its axis of molecular symmetry. Individual
polypeptide chains are in green (chain A) and
in magenta (chain B), and ligands (glucose
and Gluc-6-P) are in black. (b) Stereoview of
the 3–4 interface (defined in Table 2) and
intrachain contacts between the N- and C-
terminal domains. Mainchain elements of C-
terminal domains are drawn in bold black lines
and mainchain elements of the N-terminal
domain are drawn in open lines. Residues
belonging to chain B are marked with the
letter B; all other residues belong to chain A.
Intrachain donor–acceptor interactions
between the N- and C-terminal domains are
indicated by dashed lines and involve
Asp251, Glu252 and Arg801. The
approximate base-binding region for adenine
nucleotides is indicated by the letter A. The
position of the putative metal cation in the
loop 242–253 is indicated by a filled circle.
The figures in (a) and (b) have the same
orientation; the cross in the bottom illustration
represents the position of the molecular
twofold axis. (The illustration was generated
with MOLSCRIPT [54].)
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influence the position of the flexible subdomain in the
C-terminal half of hexokinase I (see below).
Curiously, the backbone carbonyl groups of residues 242,
245, 248 and 250 are directed towards the center of loop
242–253, where there exists distinct electron density. An
atom positioned in that electron density is approximately
2.4 Å away from each of the carbonyls, an unlikely envi-
ronment for a water molecule, but possible for a cation. In
fact, identical geometries and electron density are present
in the loop for the other N-terminal domain and in the
corresponding loops (residues 690–701) for the C-terminal
domains. Refinement of water molecules at these putative
cation sites resulted in thermal parameters under 10 Å2,
compared to an average thermal parameter of 46 Å2 for
the subset of water molecules associated with difference
electron density in excess of 3.5σ. Refinement of Ca2+ at
the four sites, however, resulted in thermal parameters
ranging from 59–92 Å2, approximately 25–40 Å2 higher
than thermal parameters of nearby atoms of the main-
chain. If the electron density is associated with a third
period transition metal, then the sites are not at full occu-
pancy in the structure reported here. In addition, these
four sites are too remote from bound ligands in this
dimer to cause the observed relaxation effects due to Mn2+
on the nuclear magnetic resonances of the 1-H atoms of
glucose and Gluc-6-P [27].
Ligand interactions
All ligands were refined with fractional occupancies of
1.0. Hence, thermal parameters for ligands reflect disorder
and the possibility of incomplete occupancy. Thermal
parameters for glucose and Gluc-6-P at the C-terminal
domain of chain A  and the N- and C-terminal domains
of chain B are relatively low and comparable to those of
nearby sidechains, indicating full occupancy for the
ligands. Thermal parameters for ligands at the N-termi-
nal domain of chain A are, however, approximately 25 Å2
higher than for nearby sidechains, reflecting partial
ligand occupancy here. The variation in thermal parame-
ters and occupancies could be an intrinsic property of the
dimer, but is most likely a consequence of packing con-
tacts in the crystal. Hence, we cannot assign the high-
affinity site for Gluc-6-P to a specific domain.
Interactions at the glucose-binding pocket (Figure 5;
Table 3), irrespective of domain, are consistent with sub-
strate specificity studies of Sols and Crane [28], which
implicate the participation of all but the 2-OH group of
glucose in ligand–protein interactions. The glucose-binding
sites of the N- and C-terminal domains exhibit well-defined
donor–acceptor relationships at the 1-, 3-, 4- and 6-OH
groups (Table 3). Bound glucose is present unequivocally
as the β-anomer. The α-anomer of glucose could bind
without steric conflict, but at the expense of perturbing
the hydrogen bond between Glu742 (Glu294, N-terminal
domain) and the 1-OH group. The 2-OH group of glucose
has a relatively weak interaction with Glu708 (Glu260);
the presence of the 2-amino group in glucosamine could
enhance interactions with Glu708 (Glu260), but perhaps at
the expense of weakened interactions between Glu708
(Glu260) and the 3-OH group of glucosamine. The above is
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Figure 5
Electron density and immediate environment
of ligands bound to hexokinase I. (a)
Stereoview of the electron density associated
with a Fobs–Fcalc exp[– iαcalc] omit map. The
cover radius is 2.0 Å and the contour level is
approximately 6σ. Putative conformational
disorder for Gluc-6-P is represented by a pair
of conformers that differ by a 15° rotation
about the O6–C6 bond. (b) Stereoview of the
active site of chain A, showing selected
residues and the ligands. Glucose and Gluc-
6-P are drawn in bold lines. 
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consistent with glucosamine acting as a substrate with a Km
comparable to that of glucose. N-acetylglucosamine and
N-methylglucosamine are potent inhibitors of hexokinase I
[28]. The N-methyl and N-acetyl groups could fit into a
narrow pocket extending from the equatorial 2-position of
the pyranose ring, but not without some perturbation either
in the position of the pyranose ring or in the conformation
of the glucose-binding pocket.
Directed mutations of Ser603, Asp657, Glu708 and Glu742
of tumor mitochondrial hexokinase I abolishes activity
[29]. Of the four residues, only Ser603 does not interact
directly with glucose (Table 3). Instead, OG of Ser603
makes a close, nonbonded contact with Asp657 and a
hydrogen bond with the 1-OH group of Gluc-6-P (Figure 5).
However, a 120° rotation about χ1 of Ser603 would allow
OG to hydrogen bond with Lys621, Asp657, and the 6-OH
group of glucose. Conceivably, Glu-6-P could perturb the
conformation of Ser603, or perhaps Ser603 adopts a dif-
ferent conformation in the presence of ATP. Directed
mutation of Ser155, Asp209, Glu260 and Glu294 (residues
of the N-terminal domain which correspond to Ser603,
Asp657, Glu708 and Glu742, respectively) results in only
small changes in activity [10]. Evidently, the binding of
glucose to the N-terminal domain, observed in the crystal
structure, may be of little consequence to catalytic events
at the C-terminal domain.
Glucose and Gluc-6-P occupy distinct binding sites on the
basis of ligand specificity studies [30], and indeed glucose
and Gluc-6-P bind at distinct sites in the structure reported
here. In harmony with the findings of Crane and Sols [30],
the 2- and 4-OH groups and the 6-phosphoryl group partic-
ipate in significant interactions (Table 3), whereas the 1-
and 3-OH groups make donor–acceptor contacts of less
certainty. In fact, the electron density associated with the
pyranose moiety of Gluc-6-P is consistent with a 15° oscil-
lation about the O6–C6 bond (Figure 5). The distances
reported in Table 3 represent one limit (that which results
directly from refinement) with respect to that oscillation,
where an interaction between the 1-OH group and Asp657
(Asp209, N-terminal domain) is favored. The other limit
(obtained by post-refinement modeling) emphasizes inter-
actions of the 3-OH group with Asp861(Asp413). Hence,
the loss of either the 1-OH group or the 3-OH group
should not seriously affect the interaction of Gluc-6-P,
other than to alter the balance between a pair of mutually
exclusive conformers. β-Methylglucoside-6-phosphate does
not inhibit hexokinase I [31]; a methyl group extending
from an equatorial 1-OH would collide with the sidechain
of Asp657(Asp209). Axial substitutions at the 1, 3 and 5
positions of Gluc-6-P have modest effects on Ki [30,31].
The Gluc-6-P binding pocket can accommodate axial
methyl or hydroxyl groups on the 1, 3 or 5 carbons with
only small perturbations in the conformation of the protein
or in the position of the pyranose ring.
Gluc-6-P inhibition of hexokinase I
The crystal structure of the dimer, in conjunction with
binding studies and kinetics, supports a mechanism
whereby the direct binding of Gluc-6-P to the C-terminal
domain causes inhibition. Firstly, the presence of robust
electron density for Gluc-6-P at the C-terminal domain is
consistent with reports of potent inhibition of the isolated
C-terminal domain by Gluc-6-P [9–11,32]. Secondly, Gluc-
6-P and ATP compete for the same binding site on the
basis of kinetics [14,19,33], and indeed, binding sites for
ATP and Gluc-6-P at the C-terminal domain probably
overlap (see below). Thirdly, the simplest explanation for
the binding synergism of glucose and Gluc-6-P is that
both ligands stabilize a common conformational state of
the C-terminal domain (see below). Fourthly, the kinetics
of the reverse reaction clearly exhibit substrate inhibition,
implying multiple binding sites for Gluc-6-P at the active
site [19]. Mehta et al. [24] suggest that Gluc-6-P binds to
the glucose pocket in the absence of glucose. Substrate
inhibition, observed in the kinetics of the reverse reaction
[19], may be due to the binding of Gluc-6-P to the site
observed in the crystal structure. On the basis of model-
ing, Gluc-6-P can bind at the glucose pocket and at the
site observed in the crystal structure. The phosphoryl
groups of the two molecules of Gluc-6-P would be in
contact, hence the elevated dissociation constant for the
second Gluc-6-P molecule. Finally, the latency hypothesis,
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Table 3
Selected contacts between protein and ligands bound to the
C-terminal domain of chain A.
Ligand atom Protein atom Distance (Å)
Glucose
O1 Glu742 OE1 2.60
O2 Thr620 OG1 3.23
Glu708 OE1 2.88
O3 Glu708 OE2 2.64
Asn656 ND2 2.62
O4 Asn656 OD1 2.90
Asp657 OD2 2.52
Asn683 ND2 3.09
O6 Asp657 OD1 3.01
Lys621 NZ 2.83
Gluc-6-P
O1 Ser603 OG 2.98
Asp657 OD1 3.07
O2 Ser897 OG 2.65
Asp532 OD2 2.77
Asp532 OD1 3.25
O3 Asp532 OD1 3.27
O4 Asp861 OD2 2.78
Asp861 OD1 3.02
O7* Thr863 N 3.06
Thr863 OG1 2.96
O8* Thr680 N 2.91
Thr680 OG1 2.93
O9* Thr536 N 2.85
Thr536 OG1 2.73
*Oxygen atom of the 6-phosphoryl group.
that no binding site for Gluc-6-P exists at the C-terminal
domain of hexokinase I until it is separated from the N-
terminal domain [2], is difficult (but not impossible) to
reconcile with the structure presented here, which clearly
reveals Gluc-6-P at the C-terminal domain.
On the other hand, not all the evidence is consistent with
the direct inhibition of the catalytic domain by Gluc-6-P.
Mutations of Thr680 and Asp532, residues which bind
directly to Gluc-6-P in the C-terminal domains of the
dimer, have significant effects on kcat [34,35], but little or no
effect on the Ki for the Gluc-6-P analog, 1,5-anhydro-D-glu-
citol [35]. To the best of our knowledge no reported muta-
tion of hexokinase I has influenced the Ki of Gluc-6-P.
The loop 532–537 of the C-terminal domain and corre-
sponding loop 84–89 of the N-terminal domain each
hydrogen bond with the 6-phosphoryl group of Gluc-6-P
and each have similar conformations. The corresponding
loops of yeast hexokinase and glycerol kinase, however,
differ significantly in conformation, even though a sulfate
anion in yeast hexokinase (Figure 3) and the phosphate
moiety of ADP in glycerol kinase (see below) occupy sites
which correspond to the 6-phosphoryl-binding sites in
hexokinase I (Figure 3). The relaxation of loop 532–537 in
the presence of Gluc-6-P may be an important factor in
the tight binding of this ligand to hexokinase I.
The binding synergism exhibited by Gluc-6-P and glucose
in hexokinase I and the isolated C-terminal domain
[9,14,24] can be explained in principle by interactions
within the C-terminal domain. As in yeast hexokinase,
some of the binding energy of glucose probably drives the
putative transition from the open to the closed conforma-
tion of the C-terminal domain of hexokinase I. Unlike
yeast hexokinase, however, an alternative binding site for
Gluc-6-P is present in the C-terminal domain, which
allows Gluc-6-P to further stabilize the closed conformer.
Indeed, Gluc-6-P cross-links the small and large subdo-
mains (Figure 2), which undergo rigid body movements in
the glucose-induced conformational change observed in
yeast hexokinase. If the binding energies of glucose and
Gluc-6-P are leveraging the same conformational transi-
tion, then one would expect synergism.
Glycerol kinase and hexokinases are members of the sugar
kinase family, being putatively related in structure as well
as function [36]. The structure determination of glycerol
kinase in its complex with glycerol phosphate and ADP [37]
maps out an adenine-binding site in general agreement
with the nonproductive complex of yeast hexokinase and
8-bromo-AMP [38]. The transformation that superimposes
a subset of conserved α carbons of glycerol kinase onto the
C-terminal domain of hexokinase I also maps the ADP mol-
ecule of the glycerol kinase complex onto the putative
adenine nucleotide site of hexokinase I. The transformed
ADP molecule is the basis for a model of ADP bound to
hexokinase I (Figure 6). The α phosphate of ADP overlaps
the 6-phosphoryl group of Gluc-6-P. Evidently, the 6-phos-
phoryl group of Gluc-6-P, which is slightly more than 6 Å
away from the 6-OH group of glucose, does not represent
the γ-phosphoryl site of ATP, but instead lies closer to
either the α- or β-phosphate binding sites of ATP. The
above model is consistent with Gluc-6-P being a competi-
tive inhibitor with respect to ATP [14] and with Gluc-6-P
protection of the C-terminal domain against modification
by the photoaffinity label 8-azido-ATP [39].
Models for the relief of Gluc-6-P inhibition by Pi
The N-terminal domain is essential in the relief of Gluc-6-P
inhibition by Pi. As the current structure reveals binding
sites for the 6-phosphoryl group of Gluc-6-P at the N- and
C-terminal domains, one of these two sites could repre-
sent the functional binding site for Pi. Concentrations of Pi
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Figure 6
Stereoview of the superposition of glycerol
kinase (green) onto the C-terminal domain of
hexokinase (orange). The ADP molecule (red)
from the glycerol kinase complex maps onto
the putative active site of hexokinase I with its
α-phosphate overlapping the 6-phosphoryl
group of Gluc-6-P (purple). Glucose, as
bound to the C-terminal domain, is in yellow.
The asterisk marks loop 532–537 of
hexokinase I. The corresponding loop of
glycerol kinase does not interact with the
phosphoryl groups of ADP. The magnesium
cation associated with ADP in the glycerol
kinase complex (not shown here for clarity),
overlaps the pyranose ring of Gluc-6-P. (The
illustration was generated with MOLSCRIPT
[54].)
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up to 1 mM do not influence the Km of ATP, but relieve
Gluc-6-P inhibition [40]. Hence, the 6-phosphoryl site for
Gluc-6-P at the C-terminal domain is an unlikely site for
the tight binding of Pi.
Assuming then that Pi binds tightly to the 6-phosphoryl site
of the N-terminal domain, two models for regulation of
hexokinase I are consistent with the crystal structure and
the literature. In the first model, Gluc-6-P binds tightly as
an allosteric inhibitor to the N-terminal domain, stabilizing
a closed conformation for that domain. The closed N-termi-
nal domain then putatively stabilizes the flexible sub-
domain of the C-terminal half in a conformation that
impedes the productive binding of ATP. Pi relieves inhibi-
tion by directly competing with Gluc-6-P at the N-terminal
domain. In the second model, Gluc-6-P binds tightly to the
C-terminal domain as an active-site inhibitor, stabilizing a
closed conformation and competing directly with ATP. Pi
binds to the N-terminal domain, again stabilizing a closed
conformation which, by way of its influence on the flexible
subdomain, stabilizes the binding of ATP to the active site.
In the second model, ATP mediates the antagonism
between Pi and Gluc-6-P, observed in the kinetics. The
models above account for the function of hexokinase I in
the presence of ATP and glucose. In the absence of glucose
and ATP, other ligand interactions evidently predominate,
as for instance, the binding of Gluc-6-P to the glucose site
of the N- or C-terminal domain [24].
Quantitative data regarding the properties of hexokinase I
in solution are not sufficient to eliminate either model,
though, as mentioned above, the second model provides
the simplest explanation for many of the observed phe-
nomena associated with hexokinase I. The two models
are distinguished by their high-affinity sites for Gluc-6-P
(N- as opposed to C-terminal domain) and by whether
the N-terminal domain in a closed state impedes or sup-
ports the productive binding of ATP. 
Biological implications
Approximately 40% of all circulating glucose goes to
support the energy metabolism of the brain. Over the
period of a single day the brain consumes 13% of its
weight in glucose. The conversion of glucose into glucose-
6-phosphate (Gluc-6-P), mediated by hexokinase I, traps
glucose in a chemical state that cannot leave the cell and
hence commits glucose to energy metabolism. Further-
more, hexokinase I has a Km for glucose which is 100
times lower than the normal concentration of circulating
glucose (5 mM). Even under conditions of starvation,
the brain will have its share of glucose for glycolysis.
However, an enzyme that maintains glycolysis even
under conditions of starvation, presents a serious meta-
bolic problem under conditions of adequate circulating
glucose. If the entire intracellular pool of glucose in the
brain is converted to Gluc-6-P, the concentration of Pi
may fall to levels that can no longer sustain oxidative
phosphorylation in the mitochondria. In order to guard
against this possibility in brain tissue, hexokinase I is
sensitive to concentrations of both Gluc-6-P and Pi.
Hence the ravenous appetite of the brain for glucose is
satisfied subject to a tight regulatory process at the first
step of glycolysis.
The structure reported here provides insight as to how
this regulatory process might occur at a molecular level.
Interactions between the N-terminal (regulatory) domain
and the C-terminal (catalytic) domain are clearly a part
of the regulatory mechanism of hexokinase I. In pub-
lished models [10,41], the N- and C-terminal domains
have relative orientations that differ significantly from
those observed in the crystal structure. The crystal struc-
ture for the first time implicates specific residues in
domain interactions and regulation. The significance of
these residues is subject to verification by site-directed
mutation and kinetics studies. The crystal structure iden-
tifies a flexible subdomain, which may interact with the
base of ATP and be a functional element in allosteric
regulation. The structural differences in this flexible sub-
domain may be responsible for the absence of a catalytic
function in the N-terminal domain. Alternative binding
sites for Gluc-6-P are disclosed here in detail for the first
time and provide a basis for a mechanism that accounts
for the observed binding synergism for glucose and Gluc-
6-P. Finally, the X-ray structure permits reasonable
speculation in assigning the high-affinity binding site for
Pi to the N-terminal domain and focuses attention on two
plausible models for the regulation of hexokinase I. A
detailed structure of hexokinase I for the first time permits
the design of experiments in directed mutation, kinetics
and spectroscopy that should establish unequivocally a
regulatory model for hexokinase I.
Materials and methods
Expression, purification and crystallization
Escherichia coli strain BL21(DE3) was transformed with a plasmid
harboring the cDNA for human hexokinase I [11,35,42]. A 100 ml
culture of the transformed E. coli was grown overnight in LB medium
plus 40 mg/L ampicillin and then added to 10 L of M9 medium. The
culture was grown in a fermentor at 37°C to early log phase
(A600 = 0.4), after which isopropyl–D-thiogalactopyranoside (IPTG)
was added to a final concentration of 0.4 mM. The culture was grown
with stirring (200 rpm) and a filtered air flow of 6 L/min for an addi-
tional 24 h at 22°C.
Hexokinase I was purified as described previously [11,35]. Typically, 20 L
of culture produced 70 mg of hexokinase I, which was pure on the basis
of SDS-PAGE (data not shown). In order to produce enzyme of sufficient
quality for crystallization, however, a final step of purification on a HPLC–
DEAE 5PW Spherogel TSK-G column, using a gradient in potassium
chloride from 0–0.5 M and a buffer of glucose (2 mM) and potassium
phosphate (25 mM), pH 7.0, resolved two closely spaced bands of
protein that could not be distinguished either by their kinetic properties
(Km, kcat, specific activity), by their molecular weights as determined by
MALDI-TOF (matrix assisted laser desorbtion ionization — time of flight),
or by N-terminal amino-acid analysis (both fractions are missing the first
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10 amino acids from the N terminus). Only the leading band produced
large single crystals of hexokinase I. The yield of crystallizable protein,
was approximately 30 mg from 20 l of culture.
Crystals of hexokinase I were grown by the hanging drop method. Hexok-
inase I, stored in a buffer of glucose (2 mM) and potassium phosphate
(25 mM), pH 7.0, was dialyzed twice against 200 volumes of potassium
phosphate solution (25 mM), pH 7.0. The protein solution was then sub-
jected to two cycles of concentration (10-fold reduction in volume by
centrifugational filtration) followed by redilution with Gluc-6-P (20 mM),
pH 7.5. A volume of 3.5 µl of the resulting solution, which contained
protein (20 mg/ml) and 20 mM Gluc-6-P, pH 7.5, was combined with an
equal volume of a precipitant solution containing 5–7% (w/v) polyethyl-
ene glycol 8000 (Sigma), 20 mM Gluc-6-P, 0.1 M sodium acetate and
0.1 M sodium citrate, pH 6.0. The drops equilibrated against 0.7 ml of
the precipitant solution. Prismatic needles of length 0.5–0.8 mm and
width 0.2–0.3 mm grew in two to three weeks. The crystals, belonging
to the space group P21 (a = 83.44 Å, b = 121.83 Å, c = 122.53 Å, andβ = 92.6°), were transferred to a solution containing 12% (w/v) polyethyl-
ene glycol 8000, 10 mM Gluc-6-P, 5 mM glucose and 0.1 M sodium
citrate, pH 6.0. The identical crystal form grew also from protein samples
that contained Gluc-6-P (20 mM) and glucose (1 mM), pH 7.5.
X-ray diffraction data
X-ray diffraction data were collected on SSRL Beam Line 7-1, using
a wavelength of 1.08 Å and an 18 cm image plate detector (MAR
Research, Hamburg) with a crystal-to-detector distance of 22 cm.
Each of 97 frames were collected over an oscillation range of 0.9°
and 15 s at a temperature of 4°C. The long axis of the prismatic
needle was oriented perpendicular to the incident beam. Approxi-
mately 10 frames could be collected before the appearance of
significant radiation damage, whereupon an unexposed region of the
crystal was translated into the incident X-ray beam. Two crystals were
necessary for a complete data set. Diffraction data were processed
with DENZO/SCALEPACK [43] and programs from the CCP4 suite
[44], with the results reported in Table 1.
Structure determination
Several lines of evidence were consistent with a hexokinase I dimer for
the asymmetric unit of the P21 crystal form prior to the structure determi-
nation. The asymmetric unit is large enough for two hexokinase I
monomers and yet has 48% of its volume occupied by water. The dimer-
ization of hexokinase I under conditions of high protein concentration and
in the presence of Gluc-6-P was indicated by ultracentrifugation studies
[26]. The self-rotation function [45,46] indicated a molecular symmetry
axis oriented within 10° of the twofold screw axis of the unit cell.
A model for yeast hexokinase A in its complex with glucose, developed
independently by (HDB et al. unpublished data), was the basis for a mol-
ecular replacement solution of the P21 crystal form. The sequence of
yeast hexokinase A was aligned to the sequence of hexokinase I as in
Figure 1. Mainchain and sidechain atoms were omitted from the yeast
hexokinase model for those regions of the sequence alignment which
diverged significantly due to insertions or deletions of residues. In regions
of the alignment which exhibited a one-to-one correspondence between
residues of different type, all mainchain and sidechain atoms up to Cγ
were retained from the yeast hexokinase model. For corresponding
residues of identical type, all atoms of the yeast hexokinase model were
retained. The molecular replacement models for the N- and C-terminal
domains contained 81% of the mainchain atoms and 76% of the total
number of atoms of yeast hexokinase in its complex with glucose.
The program AMoRe [47] was used in the calculation of rotation and
translation functions, using data to 4 Å resolution. The initial molecular
replacement solution was refined by independent, rigid-body adjust-
ments in the N- and C-terminal domains of the hexokinase I dimer using
AMoRe, which resulted in a correlation coefficient (defined with
respect to the magnitude of the structure factor) of 0.55 and an R
factor of 0.48, for data to 4 Å resolution.
Model building and refinement
Further refinement used XPLOR [48] and the parameters of energy
and stereochemistry of [49]. Only hydrogen atoms of glucose and
Gluc-6-P were represented explicitly in the refinement. Electrostatic
charges were scaled to zero. Each polypeptide chain of the hexokinase
I dimer was divided in turn into the four subdomains (subdomain 1,
residues 20–75 and 211–465; subdomain 2, residues 76–210; sub-
domain 3, residues 465–524 and 658–910; subdomain 4, residues
525–657). The eight independent subdomains were refined as rigid
bodies against data that were gradually increased to 2.8 Å resolution.
The resulting model (R factor and Rfree, 0.51) was subjected to one
cycle of simulated annealing, using an initial temperature of 3000K and
cooling in steps of 25K to a final temperature of 300K. Noncrystallo-
graphic restraints (150 kcal/mol) were applied between mainchain and
sidechain atoms, related by molecular symmetry of the dimer. The
resulting model (R factor, 0.36; Rfree, 0.44) provided phases of suffi-
cient quality to build all but the first 15 and the last 3 amino acid
residues of hexokinase I. Model building used Silicon Graphics work-
stations (Indigo2 XL) and the software TOM [50] and XTALVIEW [51].
Refinement cycles 1–6 used restraints on thermal parameters (adja-
cent mainchain atoms; 1.0 Å2; next-to-nearest mainchain atoms, 1.5 Å2;
adjacent sidechain atoms, 1.5 Å2; next-to-nearest sidechain atoms,
2.0 Å2) and restraints (100 kcal/mol) on all atoms related by noncrystal-
lographic symmetry, excluding those at lattice contacts. Ligands were
modeled against omit electron density maps based on phases from the
third cycle of refinement. In the last two cycles of refinement, prominent
waters associated with difference density in excess of 3.5 σ and con-
sistent with good hydrogen bonding were added to the model.
Superposition of models
Superposition of Cα atoms of the N-terminal domains of chains A and
B (excluding residues in the ill-defined loop 98–105), using the CCP4
package, gave a root mean square deviation (rmsd) of 0.11 Å. The cor-
responding value for the C-terminal domains (excluding the poorly
defined loop 546–551) was 0.04 Å. Superposition of the C- and N-ter-
minal domains onto each other and onto yeast hexokinase, using all
corresponding residue pairs of Figure 1, gave rmsds of 1.5 and 2.5 Å,
respectively. The exclusion of 90 pairs of Cα atoms, separated by more
than 2.3 Å after the superposition of the C-terminal domain onto yeast
hexokinase, reduced the rmsd to 1.3 Å. The exclusion of 52 pairs of Cα
atoms, separated by more than 1.5 Å after the superposition of the C-
terminal domain onto the N-terminal domain, reduced the rmsd to
0.7 Å. Superposition of glycerol kinase onto the C-terminal domain
employed Cα atoms corresponding to a subset of conserved residues
of sugar kinases [36], which gave an rmsd of 1.2 Å.
Accession numbers
Coordinates for the model have been deposited in the Protein Data
Bank (accession code 1HKB).
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